SILVER SPRING
Linzess cleared for pediatric functional constipation
- Sponsor
- Ironwood Pharmaceuticals $IRWD
- Drug
- Linzess · linaclotide
- Indication
- Functional constipation
FDA approved Linzess (linaclotide) for pediatric patients aged 2+ with functional constipation.
What this means
Linzess is a capsule that helps relieve constipation by increasing fluid in the intestines and speeding up bowel movements. FDA has now approved Linzess for children aged 2 and older who have functional constipation, a condition where bowel movements are infrequent or difficult without a clear cause. This decision gives pediatricians and families a new treatment option, though parents should watch for signs of dehydration, a known risk in children taking the drug.
Drug Watch — recent news on Linzess
- Ironwood Pharmaceuticals (IRWD) Jefferies 2024 Global Healthcare Conference Summary - Quartr
- Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap (NASDAQ:IRWD) - Seeking Alpha
- Efficacy of Linaclotide in Reducing Abdominal... : American Journal of Gastroenterology - Lippincott Home
- Linzess and Medicare: Cost and Coverage - AOL.com
- Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use - HCPLive
Sponsor Watch — recent news on Ironwood Pharmaceuticals
- REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
- The Real Question Buried Inside Merck Stock's Premium Price
- AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe
- VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients